Nephrocare Health Services IPO has successfully raised ₹2.6 billion from anchor investors, setting a strong foundation for its public issue. The IPO will open for retail investors from December 10, 2025, and is set to list on December 17, 2025, with proceeds aimed at expansion and debt repayment.
Nephrocare Health Services' IPO anchor book saw strong investor interest, with shares worth ₹2.6 billion allocated to institutional investors ahead of the main public subscription. The anchor investor segment closed on December 9, 2025, setting a positive tone for the upcoming retail and HNI bidding scheduled from December 10 to 12, 2025. The IPO is being managed by ICICI Securities, Ambit, IIFL Capital, and Nomura Financial Advisory, and the shares will be listed on both NSE and BSE.
Notable Updates:
-
Anchor investors have been allocated ₹2.6 billion worth of shares, signaling robust institutional confidence in the company’s growth prospects.
-
The IPO’s price band is set between ₹438 and ₹460 per share, with a minimum lot size of 32 shares.
-
The issue size stands at approximately ₹871 crore, comprising both a fresh issue and an offer for sale.
-
Retail investors can participate from December 10 to 12, with allotment expected by December 15 and listing slated for December 17, 2025.
Major Takeaways:
-
Anchor investors include prominent institutional names, reflecting strong market sentiment.
-
The IPO’s proceeds will be used for capital expenditure on new dialysis clinics, repayment of borrowings, and general corporate purposes.
-
Lock-in periods for anchor investors are 30 days for 50% of shares and 90 days for the remaining portion.
Important Points:
-
The company reported steady growth in revenue and profitability, with a PAT of ₹67.10 crore for FY2025.
-
Promoter holding will decrease post-issue, with increased public float.
-
The IPO is expected to be oversubscribed, given the sector’s resilience and the company’s expanding footprint.
Source: NSE Circular, Zerodha, IPO Watch, Samco, Chittorgarh, IPO Platform